# A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC

Source: https://onco.cc/trials/nct07567521/  
OnCo record `nct07567521` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Radiopharmaceuticals in prostate cancer, run by C Ray Therapeutics, now recruiting.

## Summary

A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC is a phase 1/2 interventional study registered as NCT07567521 by C Ray Therapeutics, with 90 participants planned, started 2026-05-22 and due to reach its primary completion in 2027-12-30. Interventions recorded: Radiopharmaceuticals.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07567521
- Phase: 1/2
- Setting: A Prospective, Open-label, Randomized, Phase 1/2 Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Sponsor: C Ray Therapeutics
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT07567521: https://clinicaltrials.gov/study/NCT07567521

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)

---
JSON: https://onco.cc/api/v1/entities/nct07567521.json